Authors: Hirotaka Kato, Tomohide Tsukahara, Kenji Murata, Hiromu Nishikata, Yuka Mizue, Takashi Sasaya, Terufumi Kubo, Takayuki Kanaseki, Yoshihiko Hirohashi, Atsushi Oyagi, Tatsuo Maeda, Akihiro Miyazaki. and Toshihiko Torigoe
Cancer Immunology, Immunotherapy, 04 March 2025
Researchers use Axion BioSystems’ versatile Maestro Z platform to track immune cell-mediated killing in vitro with no labels or dyes.
Immunotherapies have been very successful for treating liquid tumors like leukemia and lymphoma, but the development of effective immunotherapies for solid tumors remains challenging. In this study, researchers who had previously identified PVT1 as a potential solid tumor target seek to target PVT1 with a novel bispecific T cell engaging antibody (BiTE), using Axion BioSystems’ Maestro Z live-cell analyzer to assess T cell-mediated cytotoxicity of the BiTE construct (HF10xCD3) against PVT1+ tumor lines. The results showed that HF10xCD3 demonstrated significantly increased potency against PVT1+ tumor lines compared to T cell treatment alone. Additionally, HF10xCD3 did not induce increased cytotoxicity against PVT1- lines, further suggesting target specificity. Overall, the authors conclude that “HF10xCD3 holds significant promise for antibody-based therapies aimed at treating various solid tumors, including carcinomas and bone sarcomas.”
